<SEC-DOCUMENT>0001140361-21-020816.txt : 20210614
<SEC-HEADER>0001140361-21-020816.hdr.sgml : 20210614
<ACCEPTANCE-DATETIME>20210614170029
ACCESSION NUMBER:		0001140361-21-020816
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20210613
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20210614
DATE AS OF CHANGE:		20210614

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Brooklyn ImmunoTherapeutics, Inc.
		CENTRAL INDEX KEY:			0000748592
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				311103425
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11460
		FILM NUMBER:		211015299

	BUSINESS ADDRESS:	
		STREET 1:		140 58TH STREET, BUILDING A
		STREET 2:		SUITE 2100
		CITY:			BROOKLYN
		STATE:			NY
		ZIP:			11220
		BUSINESS PHONE:		(212) 582-1199

	MAIL ADDRESS:	
		STREET 1:		140 58TH STREET, BUILDING A
		STREET 2:		SUITE 2100
		CITY:			BROOKLYN
		STATE:			NY
		ZIP:			11220

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTN BUZZTIME INC
		DATE OF NAME CHANGE:	20051230

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTN COMMUNICATIONS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ALROY INDUSTRIES INC
		DATE OF NAME CHANGE:	19850411
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>brhc10025807_8k.htm
<DESCRIPTION>8-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using EDGARfilings PROfile 7.5.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 14pt; font-weight: bold;">UNITED STATES</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
      <div><br>
      </div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 18pt; font-weight: bold;">FORM 8-K</div>
      <div><br>
      </div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">CURRENT REPORT</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</div>
      <div><br>
      </div>
      <div style="text-align: center; color: rgb(0, 0, 0);">Date of Report (Date of earliest event reported): <font style="font-weight: bold;">June 13, 2021</font></div>
      <div><br>
      </div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 24pt; font-weight: bold;">BROOKLYN IMMUNOTHERAPEUTICS, INC.</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-style: italic;">(Exact Name of Registrant as Specified in its Charter)</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z4c0bf8b668124b268aee858142ebab10" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 33.33%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Delaware</div>
            </td>
            <td style="width: 34%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">001-11460</div>
            </td>
            <td style="width: 33.33%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">31-1103425</div>
            </td>
          </tr>
          <tr>
            <td style="width: 33.33%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-style: italic;">(State or Other Jurisdiction of Incorporation)</div>
            </td>
            <td style="width: 34%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-style: italic;">(Commission File Number)</div>
            </td>
            <td style="width: 33.33%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-style: italic;">(IRS Employer Identification No.)</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="zfac48b0506ab4801935ed0be02533b58" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 49%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">
                <div style="color: rgb(0, 0, 0); font-weight: bold;">140 58<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Street, Building A, Suite 2100</div>
              </div>
            </td>
            <td style="width: 2%; vertical-align: bottom;">&#160;</td>
            <td style="width: 49%; vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 49%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Brooklyn, New York</div>
            </td>
            <td style="width: 2%; vertical-align: bottom;">&#160;</td>
            <td style="width: 49%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">11220</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-style: italic;">(Address of Principal Executive Offices)</div>
            </td>
            <td style="width: 2%; vertical-align: bottom;">&#160;</td>
            <td style="width: 49%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-style: italic;">(Zip Code)</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: center; color: rgb(0, 0, 0);">Registrant&#8217;s telephone number, including area code: <font style="font-weight: bold;">(212) 582-1199</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
        following provisions:</div>
      <div><br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z03a90df23bbb4f75bcc868edebeaed8d" class="DSPFListTable">

            <tr style="vertical-align: top;">
              <td style="vertical-align: top; width: 18pt;">&#9744;</td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;"><font style="color: rgb(0, 0, 0);">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z606dc8ae36b84e8485d56ae996bdeb9d" class="DSPFListTable">

            <tr style="vertical-align: top;">
              <td style="vertical-align: top; width: 18pt;">&#9744;</td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;"><font style="color: rgb(0, 0, 0);">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z4a73ca91246d4515bddefbd94c09a1e1" class="DSPFListTable">

            <tr style="vertical-align: top;">
              <td style="vertical-align: top; width: 18pt;">&#9744;</td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;"><font style="color: rgb(0, 0, 0);">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zee08f0dc95c84e5ea560d8bec5234d6b" class="DSPFListTable">

            <tr style="vertical-align: top;">
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;"><font style="font-family: 'Segoe UI Symbol',sans-serif; color: rgb(0, 0, 0);">&#9744;</font></div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;"><font style="color: rgb(0, 0, 0);">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div style="text-align: center; color: rgb(0, 0, 0);">Securities registered pursuant to Section 12(b) of the Act:</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z1dfbee8ec01a420a9a34f64f8a655135" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 40%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Title of each class</div>
            </td>
            <td style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 20%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Trading symbol</div>
            </td>
            <td style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 38%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Name of each exchange on which registered</div>
            </td>
          </tr>
          <tr>
            <td style="width: 40%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0);">Common Stock, par value $0.005 per share</div>
            </td>
            <td style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 20%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0);">BTX</div>
            </td>
            <td style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 38%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0);">NYSE American</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the
        Securities Exchange Act of 1934:</div>
      <div style="text-align: justify; color: rgb(0, 0, 0);"> <br>
      </div>
      <div style="text-align: right; color: rgb(0, 0, 0);">Emerging growth company&#160; &#9744;</div>
      <div><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new
        or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160; &#9744;<font style="font-family: 'Segoe UI Symbol', sans-serif;"></font></div>
      <div style="text-align: justify; color: rgb(0, 0, 0);"><font style="font-family: 'Segoe UI Symbol', sans-serif;"> <br>
        </font></div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><font style="font-family: 'Segoe UI Symbol', sans-serif;"> </font></div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageFooter"></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div id="DSPFPageHeader"></div>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z65807b93c7c74bdaa2373c57b31a9848" class="DSPFListTable">

            <tr style="vertical-align: top;">
              <td style="vertical-align: top; width: 54pt;">
                <div style="text-align: left;"><font style="font-weight: bold; color: rgb(0, 0, 0);">Item 8.01</font></div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;"><font style="font-weight: bold; color: rgb(0, 0, 0);">Other Events.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <div><br>
        </div>
      </div>
      <div>
        <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; color: rgb(0, 0, 0);">On June 14, 2021, we announced that we had entered into a non-binding letter of intent to acquire Novellus
          Therapeutics Limited, or Novellus, a privately held company that is based in Cambridge, Massachusetts and that develops next-generation engineered mesenchymal stem cell therapies using patented mRNA cell reprogramming and gene editing
          technologies licensed from Factor Bioscience Limited. The letter of intent, which we entered into with Novellus on June 13, 2021, proposes that we would acquire all of the outstanding equity of Novellus or its parent entity in exchange for
          consideration valued at $125.0 million, of which $17.4 million would be paid in cash and $107.6 million would be paid by issuance of shares of common stock. In the letter of intent, we and Novellus expressed our intent to seek to close the
          transaction by July 15, 2021.</div>
        <div><br>
        </div>
        <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; color: rgb(0, 0, 0);">The terms of the letter of intent with respect to the proposed transaction &#8212; including the parties&#8217;
          obligations to proceed with the transaction, the structure and timing of the transaction, and the consideration we would pay in the transaction &#8212; are not binding upon the parties. Either party may determine not to proceed with the transaction at
          any time in its discretion. The completion of the transaction is subject to a number of conditions, including completion of mutually satisfactory due diligence, execution of a definitive agreement and satisfaction of the conditions contained
          therein, and receipt of all required corporate, regulatory and other third&#8209;party approvals. No assurances can be made that we will successfully negotiate and enter into a definitive agreement or that the proposed transaction will be closed on the
          terms or timeframe contemplated by the letter of intent, or at all.</div>
        <div><br>
        </div>
        <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; color: rgb(0, 0, 0);">Our wholly owned subsidiary Brooklyn ImmunoTherapeutics LLC is party to an exclusive license agreement dated
          April 26, 2021 with Factor Bioscience Limited and Novellus Therapeutics Limited, under which Brooklyn ImmunoTherapeutics LLC acquired an exclusive worldwide license to develop and commercialize certain cell-based therapies to treat cancer and
          rare blood disorders, including sickle cell disease, based on patented technology and know-how. For a further description of this license agreement, please see the Current Report on Form 8-K that we filed with the Securities and Exchange
          Commission on April 30, 2021.</div>
        <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; color: rgb(0, 0, 0);"> <br>
        </div>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageFooter"></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div id="DSPFPageHeader"></div>
      </div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">SIGNATURE</div>
      <div><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the
        undersigned, hereunto duly authorized.</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="zb43efc806cb14a048dbb13ef256c6cb3" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 49.96%; vertical-align: top;">
              <div>&#160;</div>
            </td>
            <td style="vertical-align: top;" colspan="2">
              <div style="color: rgb(0, 0, 0);">BROOKLYN IMMUNOTHERAPEUTICS, INC.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.96%; vertical-align: top;">
              <div>&#160;</div>
            </td>
            <td style="vertical-align: top;" colspan="2">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.96%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">&#160;Dated: June 14, 2021</div>
            </td>
            <td style="width: 2%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">By:</div>
            </td>
            <td style="width: 48%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: rgb(0, 0, 0);">/s/ Howard J. Federoff</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.96%; vertical-align: top;">
              <div>&#160;</div>
            </td>
            <td style="width: 2%; vertical-align: top;">
              <div>&#160;</div>
            </td>
            <td style="width: 48%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Howard J. Federoff</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.96%; vertical-align: top;">
              <div>&#160;</div>
            </td>
            <td style="width: 2%; vertical-align: top;">
              <div>&#160;</div>
            </td>
            <td style="width: 48%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Chief Executive Officer and President</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><br>
      </div>
    </div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
